Építés alatt – nem éles oldal
Belépés
Befejeződött1/2. fázis

A Study of CM326 in Patients With Chronic Rhinosinusitis With Nasal Polyps

A legfontosabb adatok

Ki végzi
Keymed Biosciences Co.Ltd
Hol
Kína1 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Befejeződött
Fázis
1/2. fázis
Résztvevők
88 fő vett részt
Kezdés
2022. júl. 11.
Befejezés
2024. márc. 29.
A vizsgálat típusa
Beavatkozással járó, 4 csoport
A vizsgált kezelések
  • CM326
  • Placebo
A regiszteradat frissítve
2024. november 8.

Ki vehet részt

Életkor
18 év – 70 év
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 27 feltétel megnézéseKevesebb

Ki vehet részt

  • Subjects who are capable of understanding the nature of the study and voluntarily signing the ICF
  • Male or female subjects, aged between 18 and 70 years old (inclusive), with a body mass index (BMI) ≥ 19 kg/m2
  • Diagnosed with Chronic Rhinosinusitis With Nasal Polyps
  • The total NPS score should be at least 3 points, with at least 1 point in each side of the nasal cavity
  • Prior treatment with systemic corticosteroids (SCS) within two years before screening, and/or contraindicate to or intolerance to systemic corticosteroids, and/or with prior surgery to nasal polyps 6 months before the screening
  • Ongoing symptoms for at least 4 weeks before screening:1) Nasal congestion/obstruction; 2) Other symptom, e.g., loss of smell or rhinorrhea

Ki nem vehet részt

  • Have used of systemic immunosuppressants for inflammatory or autoimmune diseases within 8 weeks or 5 half-lives prior to randomization
  • Have initiated leukotriene receptor antagonist therapy within 4 weeks prior to randomization
  • have received allergen-specific immunotherapy that initiated within 3 months prior to randomization or planned to be initiated during the study period
  • Have undergone nasal surgery (including nasal polypectomy) within 6 months prior to screening
  • Have received medium- and short-acting systemic corticosteroids (including oral, intravenous, intramuscular corticosteroids), nasal dripping corticosteroids, traditional Chinese medicine (including systemic and local herbal products preparations) for chronic rhinosinusitis (CRS) within 4 weeks prior to screening, or long-acting systemic corticosteroids
  • With concomitant asthma (including suspected diagnosis of asthma) will be excluded if they meet the following conditions: predicted FEV1 of≤ 60%, or acute exacerbation of asthma within 3 months prior to screening requiring SCS or hospitalization (> 24 hours), or using inhaled corticosteroids (ICS) of > 1000 μg fluticasone propionate or others at equivalent doses
  • Have received live attenuated vaccines within 12 weeks prior to randomization, or during the planned study; or have received inactivated vaccines (e.g., novel coronavirus vaccines) within 30 days prior to randomization
  • With a history of large alcohol consumption or a history of drug abuse within 3 months prior to screening
  • Allergic or intolerant to mometasone furoate spray or CM326/placebo
  • With allergic granulomatous angiitis (Churg-Strauss syndrome), granulomatosis with polyangiitis (Wegener's granulomatosis), Young's syndrome, Kartagener's syndrome or other dyskinetic ciliary syndromes, cystic fibrosis
  • With acute sinusitis, nasal infection, or upper respiratory tract infection at screening
  • Have symptoms or whose CT scan suggests allergic fungal sinusitis
  • With malignant or benign neoplasm of nasal cavities
  • With other uncontrolled serious diseases or recurrent chronic diseases
  • Have severe hepatic and renal impairment
  • With known or suspected immunosuppression, including, but not limited to, the history of invasive opportunistic infections
  • With other medical or non-medical conditions that are not suitable for participation in the study in the opinion of the investigator
  • With antrochoanal polyps
  • With severe deviation of the nasal septum occludes at least one nostril
  • With persistent rhinitis medicamentosas
  • Subjects who are pregnant or planning to become pregnant, or breastfeeding during the study

Hol van ez a vizsgálat?

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

This is a multi-center, randomized, double blind, placebo-controlled, dose escalation study to evaluate the safety, tolerability, PK, PD, immunogenicity and preliminary efficacy of CM326 in patients with chronic rhinosinusitis with nasal polyps.

A vizsgálat 4 csoportja

  • Group 1: 55mg Q2WA vizsgált kezelés

    CM326 55 mg or matched placebo, every 2 weeks, subcutaneous (SC)

    Kezelés: CM326 és Placebo

  • Group 2: 110mg Q2WA vizsgált kezelés

    CM326 110 mg or matched placebo, every 2 weeks, subcutaneous (SC)

    Kezelés: CM326 és Placebo

  • Group 3: 220mg Q2WA vizsgált kezelés

    CM326 220 mg or matched placebo, every 2 weeks, subcutaneous (SC)

    Kezelés: CM326 és Placebo

  • Group 4: 220mg Q4WA vizsgált kezelés

    CM326 220mg or matched placebo, every 4 weeks, subcutaneous (SC)

    Kezelés: CM326 és Placebo

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Randomized, Double Blind, Placebo-controlled, Dose Escalation Phase 1b/2a Study to Evaluate the Safety, Tolerability, PK, PD, Immunogenicity and Preliminary Efficacy of CM326 in Patients With Chronic Rhinosinusitis With Nasal Polyps
Publikációk
A regiszteradat frissítve
2024. november 8.